Stock Analysis

When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?

NYSE:TDOC
Source: Shutterstock

While Teladoc Health, Inc. (NYSE:TDOC) might not be the most widely known stock at the moment, it received a lot of attention from a substantial price increase on the NYSE over the last few months. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Today I will analyse the most recent data on Teladoc Health’s outlook and valuation to see if the opportunity still exists.

Check out our latest analysis for Teladoc Health

What's The Opportunity In Teladoc Health?

Great news for investors – Teladoc Health is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $31.51, but it is currently trading at US$19.02 on the share market, meaning that there is still an opportunity to buy now. Although, there may be another chance to buy again in the future. This is because Teladoc Health’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

What does the future of Teladoc Health look like?

earnings-and-revenue-growth
NYSE:TDOC Earnings and Revenue Growth December 12th 2023

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Teladoc Health's earnings over the next few years are expected to increase by 99%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? Since TDOC is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on TDOC for a while, now might be the time to enter the stock. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy TDOC. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.

If you'd like to know more about Teladoc Health as a business, it's important to be aware of any risks it's facing. At Simply Wall St, we found 2 warning signs for Teladoc Health and we think they deserve your attention.

If you are no longer interested in Teladoc Health, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Valuation is complex, but we're here to simplify it.

Discover if Teladoc Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.